不同手术方式对治疗甲状腺微小乳头状癌的预后

doi:10.3969/j.issn.1000-8535.2016.05.015

广州医药 ›› 2016, Vol. 47 ›› Issue (5): 42-44.DOI: 10.3969/j.issn.1000-8535.2016.05.015

不同手术方式对治疗甲状腺微小乳头状癌的预后

李燕文, 廖碧玲, 曹天生

广州市花都区人民医院手术室普外科(广州 510800)

收稿日期:2016-05-24 出版日期:2016-09-20 发布日期:2021-12-02
通讯作者: 曹天生,E-mail: caotiansheng2088@sina.com

Prognosis of papillary thyroid microcarcinoma from different operation approaches

Li Yanwen, Liao Biling, Cao Tiansheng

General Surgery Department of People's Hospital of Huadu Distict, Guangzhou 510800,China

Received:2016-05-24 Online:2016-09-20 Published:2021-12-02

摘要/Abstract

摘要： 目的追踪随访186例甲状腺微小乳头状癌(Papillary Thyroid Microcarcinoma,PMC)患者术后5年及10年的肿瘤复发率、生存率、及术后并发症,探讨不同手术方式对治疗甲状腺微小乳头状癌预后。方法临床资料为1993—2003年收治的186例甲状腺微小乳头状癌患者,102例行患侧甲状腺大部分切除术(Ⅰ组),84例行患侧甲状腺全切术+峡部切除+对侧甲状腺大部分切除+中央区淋巴结清扫术(Ⅱ组)。结果 Ⅰ组患者术后5年及10年期间肿瘤复发率、生存率与Ⅱ组差别无统计学意义(P﹥0.05),对比I组,Ⅱ组患者术后发生甲状腺及甲状旁腺功能低下的发生率较高,且差别有统计学意义(P﹤0.05)。结论甲状腺微小乳头状癌预后良好,实行患侧甲状腺大部分切除术对治疗甲状腺微小乳头状癌是安全可行的。

关键词: 甲状腺微小乳头状癌, 手术方式, 预后

Abstract: Objective To follow-up 186 cases of papillary thyroid microcarcinoma and analyse their tumor recurrence rate、survival rate and complicationg after 5 and 10 years postoperation, to investigate prognosis of papillary thyroid microcarcinoma from different operation approaches. Methods 186 cases of papillary thyroid microcarcinoma were from 1993 to 2003. All the patients were divided into two groups,102 cases(group Ⅰ) performed with resection of the majority of thyroid gland, and 84 caces(group Ⅱ) performed with total thyroidectomy, thyroidectomy+isthmus thyroidectomy+contralateral thyroid lobectomy+central lymph node ablation. Results The recurrence and survival rates after 5 and 10 years were not significantly different between the two groups, but compared group Ⅰ, the incidences of hypocalcemia and hypothyroidism were higher in group Ⅱ(P<0.05). Conclusion Papillary thyroid microcarcinoma had better prognosis. Resection of the majority of thyroid gland treating papillary thyroid microcarcinoma is safe and feasible.

Key words: Papillary Thyroid Microcarcinoma, Operation Aproach, Prognosis

李燕文, 廖碧玲, 曹天生. 不同手术方式对治疗甲状腺微小乳头状癌的预后[J]. 广州医药, 2016, 47(5): 42-44.

Li Yanwen, Liao Biling, Cao Tiansheng. Prognosis of papillary thyroid microcarcinoma from different operation approaches[J]. Guangzhou Medical Journal, 2016, 47(5): 42-44.

参考文献

[1] VIRK RK, VAN DYKE AL, FINKELSTEIN A, et al. BRAF(V600E) mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation[J]. Modern pathology, 2012,27(2):161-165.
[2] 沈樑,张帅,古维立,等.甲状腺肿瘤血管内皮生长因子,环氧合酶-2表达和临床意义[J]. 现代医院,2014,4(40):11-14.
[3] 巫泓生,张帅,古维立.有关甲状腺癌肿瘤标志物的探讨[J]. 实用医学, 2009, 25(22):3900-3902.
[4] LOMBARDI CP, BELLANTONE R, DE CREA C, et al. Papillarythyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area[J]. World J Surg, 2010,34 (6): 1214-1221.
[5] SO YK, SON YI, HONG SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections[J]. Surgery, 2010,148(3): 526-531.
[6] YU XM, LLOYD R, CHEN H. Current treatmentof papillarythyroid microcarcinoma[J]. Adv Surg, 2012, 46:191-203.
[7] LONDERO SC, KROGDAHL A, BASTHOLT L, et al. Papillarythyroid microcarcinoma in Denmark 1996-2008: A national study of epidemiology and clinical significance[J]. Thyroid, 2013, 58(4):301-309.
[8] LIM YC, CHOI EC, YOON YH, et al. Central lymph node metastases in unilateral papillary thyroid microcarcinoma[J]. Br J Surg, 2009,96(3):253-257.
[9] HYUN SM, SONG HY, KIM SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillarythyroid microcarcinoma[J]. Ann Surg Oncol, 2012,19(2): 591-6.
[10] CALISKAN M, PARK JH, JEONG JS, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma[J]. Endocr J, 2012,59(4):305-311.
[11] SO YK, SEO MY, SON YL. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications[J]. Surgery, 2012,151(2):192-198.
[12] 唐国文.甲状腺癌术后患者生活质量评估[J]. 广州医药,2014,1(45):42-44.

[1]	肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.
[2]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[3]	谢艳林, 董燕, 柳建华. 经胸超声心动图在Stanford A型主动脉夹层的诊断及预后评估中的价值[J]. 广州医药, 2021, 52(3): 36-40.
[4]	罗水妹, 黄颂平, 许白兰, 沈冰寒. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.
[5]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[6]	刘霞, 方喜生, 翁成荫, 伍勇, 毛海波, 李宝秀, 王丽娜, 刘国龙. 原发性肝癌患者循环肿瘤细胞检测及其与术后复发转移的关系[J]. 广州医药, 2020, 51(2): 36-39.
[7]	李赟, 李勇, 巩平, 李小英, 李娜. 中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义[J]. 广州医药, 2020, 51(1): 59-65.
[8]	张春燕, 张赐理. 幽门螺杆菌感染与儿童过敏性紫癜患病及预后的相关性研究[J]. 广州医药, 2018, 49(4): 79-81.
[9]	李冠博. 控制性减压术对重型颅脑损伤患者神经功能、颅内压及预后的影响[J]. 广州医药, 2018, 49(2): 114-116.
[10]	谭小燕, 尹龙燕, 李凌. 乳腺恶性肿瘤患者诊断及治疗方法动态变化[J]. 广州医药, 2018, 49(1): 18-21.
[11]	刘丽, 魏莲, 袁利, 王立辉, 易艳妮. 长链非编码RNA LINC00672与肺癌预后的关联研究[J]. 广州医药, 2017, 48(4): 7-11.
[12]	陆森. 血清铁蛋白及超敏C反应蛋白联合检测对急性脑出血患者临床意义分析[J]. 广州医药, 2017, 48(4): 100-103.
[13]	赵海波, 吴永定, 曾彦茹, 杨盛帮, 李博伟, 梁宇翔. NEK2与前列腺癌预后的相关研究[J]. 广州医药, 2017, 48(2): 1-5.
[14]	许昕, 李庆山, 朱志刚, 杜庆华, 钟伟杰, 赵紫媛. Th17细胞在不同国际预后指数组DLBCL中的表达及意义[J]. 广州医药, 2016, 47(5): 14-16.
[15]	卫安娜, 杜正新, 庞慧敏. 肺结核合并呼吸衰竭脑钠肽浓度变化的临床意义[J]. 广州医药, 2016, 47(1): 6-8.

不同手术方式对治疗甲状腺微小乳头状癌的预后

Prognosis of papillary thyroid microcarcinoma from different operation approaches

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价